My ePortfolio Register   

Hypomethylating agents for relapsed and refractory acute myeloid leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.12.17
Views: 423

Dr Maximilian Stahl - Yale Cancer Center, New Haven, USA

Dr Stahl speaks with ecancer at the ASH 2017 annual meeting about the use of hypomethylating agents for relapsed and refractory acute myeloid leukaemia the impact of the administration schedule and mutational profile on outcomes.

He describes how changes in dose scheduling and 

Dr Stahl also spoke with ecancer about immune suppression for MDS patients, here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence